argenx SE (VIE:ARGX)

Austria flag Austria · Delayed Price · Currency is EUR
793.00
+3.80 (0.48%)
At close: Dec 4, 2025
36.44%
Market Cap 47.19B
Revenue (ttm) 3.14B
Net Income (ttm) 1.31B
Shares Out n/a
EPS (ttm) 19.83
PE Ratio 36.11
Forward PE 31.15
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Average Volume 4
Open 791.60
Previous Close 789.20
Day's Range 791.60 - 793.00
52-Week Range 457.20 - 805.00
Beta n/a
RSI 60.26
Earnings Date Feb 26, 2026

About argenx SE

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYGART and VYGART HYTRULO to treat generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative and ocular gMG, thyroid eye diseases, ITP, myositis, Sjögren’s disease, lupus nephropathy, systemic sclerosis, ... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2008
Employees 1,599
Stock Exchange Vienna Stock Exchange
Ticker Symbol ARGX
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

There is no news available yet.